RENEW OR SUBSCRIBE TO PPM
Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All Headache Articles

Men with chronic migraine have been shown to be at a high risk of sleep apnea and other disorders.
Amgen, Novartis, Alder, Allergan, BioHaven, Lilly, and Teva are all anticipating FDA approval of their novel anti-CGRP chronic migraine preventive medications in 2018
CGRP receptor antagonists have been well tolerated in studies.
Findings challenge a 2006 FDA advisory, questioning its validity
Lilly survey results point to need for new headache and migraine treatments as well as patient education.
Diagnosing medication overuse headache, versus medication overuse, can be a tough task for practitioners. Here's how to differentiate the two.
While migraines are an acute pain issue for many, promising results for ubrogepant are encouraging.
Two New Pain Relief Stimulators May Alleviate Chronic Pain from Cluster Headaches & Migraines
Device from Cefaly Technology promises to abort migraines more effectively than triptans.
A patient’s perception of stress appears to offer a good forecast factor to predict the onset of episodic migraines.
Three case studies and a review of current practice guidelines offer insight into treating patients with chronic pain and other symptoms after a sport-related concussion.
Two studies published in the New England Journal of Medicine report favorable results when targeting calcitonin gene-related peptide with mAb treatments for migraine pain.
A new study demonstrated that dermal application of zolmitriptan may provide significant relief from headache pain and most bothersome migraine symptoms.
John Claude Krusz, PhD, MD, provides 6 case reports where he as employed IV propofol in his out-patient clinic) to effectively management otherwise intractable migraine headaches.
For patients with migraines, defining the migraine will ensure proper selection of the medications and complementary therapies based on individual needs to address comorbidities and patient preferences.
SHOW MAIN MENU
SHOW SUB MENU